CorticorpNews
Back to Finance
Expand

Updated

Eli Lilly reported that its daily Foundayo obesity pill eased sleep apnea in a late-stage trial. The company plans to file by the end of the year for U.S. approval for moderate-to-severe obstructive sleep apnea in adults with obesity. The result was reported on November 9, 2026. The coverage did not include trial figures or details on the timing of any regulatory decision.

Sources:CNBC Top News

1 outlet · 1 article · first seen Nov 9, 10:10 AM ET

What this touches in markets

Stored closes for the instruments tied to this story's tags and places, with their dates.

  • LLY closed at 1432.29, up 1.44%, on 2026-11-10. Listed for: ticker the story is tagged with.
  • XLV closed at 188.88, up 0.29%, on 2026-11-10. Listed for: Health Care sector ETF.

Every source article

Corroborated by 1 outlet (GDELT)